)

Hofseth BioCare (HBC) investor relations material
Hofseth BioCare Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Q2 2025 was a transitional quarter with lower revenues but significant gross margin expansion to 46% from 34% year-over-year, reflecting a strategic shift toward higher-value human and pet health products.
Operational EBITDA turned positive at NOK 1.3 million, up from NOK -2.5 million in Q2 2024, despite one-time restructuring charges.
Human B2B segment saw 180% revenue growth year-over-year, driven by strong demand in Europe, China, and Southeast Asia, and a major global product launch.
Consumer and Pet Health (B2C) revenues were flat, but net profitability improved by 10%, with growth expected to accelerate in H2 as supply constraints ease.
R&D pipeline advanced with key studies in bone, joint, cognitive, and oncology health, and new publications and awards for flagship products.
Financial highlights
Q2 2025 operating revenue was NOK 68.4 million, down from NOK 80.4 million in Q2 2024; H1 2025 revenue was NOK 129.3 million, nearly flat year-over-year.
Gross margin rose to 46% from 34% in Q2 2024, reflecting a shift away from commodity sales.
EBITDA was NOK -5.4 million, but adjusted Operational EBITDA was NOK 1.3 million, excluding NOK 3.0 million in restructuring and other non-recurring costs.
EBIT for Q2 was NOK -14.9 million (Q2 2024: NOK -11.6 million); net financial items worsened to NOK -10.1 million due to new loans.
Cash flow from operations was negative NOK 34.2 million, mainly due to increased inventory and changes in receivables/payables.
Cash and cash equivalents at quarter-end were NOK 68.0 million, with total liquidity (including credit lines) at NOK 76.5 million.
Equity ratio at group level dropped to 0.1% (Q2 2024: 35.7%), but parent company Covenant Equity Ratio remained compliant at 29.4%.
Outlook and guidance
H2 2025 is expected to deliver over 20% revenue growth in B2C, with supply chain constraints anticipated to be fully resolved by Q4.
Softgels business forecasted to grow over 50% in the next 12 months as new customer listings and supply improvements take effect.
Continued focus on margin expansion, operational discipline, and science-led innovation to drive long-term value creation.
Next Hofseth BioCare earnings date

Next Hofseth BioCare earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage